Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HEREDITARY CANCER TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EUROPE HEREDITARY CANCER TESTING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER
6.1.2 INCREASE IN THE GERIATRIC POPULATION
6.1.3 RISING HEALTHCARE SPENDING
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING
6.2 RESTRAINTS
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING
6.2.2 LACK OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES
6.4 CHALLENGES
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS
7 EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE
7.1 OVERVIEW
7.2 MULTI PANEL TEST
7.3 SINGLE-SITE GENETIC TEST
8 EUROPE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE
8.1 OVERVIEW
8.2 BIOPSY
8.2.1 NEEDLE BIOPSIES
8.2.2 ENDOSCOPIC BIOPSIES
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY
8.2.4 LAPAROTOMY AND THORACOTOMY
8.2.5 OTHERS
8.3 IMAGING
8.3.1 MAGNETIC RESONANCE IMAGING (MRI)
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 NUCLEAR SCAN
8.3.5 ULTRASOUND
8.3.6 X-RAYS
8.4 LAB TESTS
8.4.1 BLOOD
8.4.2 URINE
8.4.3 OTHERS
9 EUROPE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION (PCR)
9.3 SEQUENCING
9.4 MICRO ARRAY
10 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME
10.3 COWDEN SYNDROME
10.4 LYNCH SYNDROME
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
10.7 LI-FRAUMENI SYNDROME
10.8 VON HIPPEL-LINDAU DISEASE
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME
11 EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 RADIOLOGY CENTERS
11.6 LABORATORIES
11.7 OTHERS
12 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 EUROPE HEREDITARY CANCER TESTING MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K.
13.1.4 RUSSIA
13.1.5 ITALY
13.1.6 SPAIN
13.1.7 TURKEY
13.1.8 NETHERLANDS
13.1.9 SWITZERLAND
13.1.10 BELGIUM
13.1.11 REST OF EUROPE
14 EUROPE HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 ILLUMINA, INC. (2021)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PERKINELMER INC. (2021)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 LIFELABS GENETICS
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 EUROFINS SCIENTIFIC (2021)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AMBRY GENETICS
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 BIOCARTIS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIO-HELIX
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CENTOGENE N.V. (2021)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 FULGENT GENETICS
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 INVITAE CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 NATERA, INC. (2021)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 4BASECARE.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE MULTI PANEL TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE SINGLE-SITE GENETIC TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 5 EUROPE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE IMAGING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE IMAGING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 12 EUROPE POLYMERASE CHAIN REACTION (PCR) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE SEQUENCING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE MICROARRAY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE HEREDITARY BREAST & OVARIAN CANCER SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE COWDEN SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE LYNCH SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE FAMILIAL ADENOMATOUS POLYPOSIS (FAP) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE LI-FRAUMENI SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE VON HIPPEL-LINDAU DISEASE IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 25 EUROPE HOSPITALS CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE CLINICS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE DIAGNOSTIC CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE RADIOLOGY CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE LABORATORIES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE OTHERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 EUROPE DIRECT TENDER IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RETAIL SALES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 37 EUROPE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 41 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 42 EUROPE HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 43 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 45 GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 46 GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 47 GERMANY HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 48 GERMANY BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 49 GERMANY IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 50 GERMANY LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 51 GERMANY HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 GERMANY HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 53 GERMANY HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 54 GERMANY HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 56 FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 57 FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 58 FRANCE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 59 FRANCE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 60 FRANCE IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 61 FRANCE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 62 FRANCE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 63 FRANCE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 64 FRANCE HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 65 FRANCE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 U.K. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 67 U.K. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 68 U.K. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 69 U.K. HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 70 U.K. BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.K. IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 72 U.K. LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.K. HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 74 U.K. HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.K. HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 76 U.K. HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 78 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 79 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 80 RUSSIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 81 RUSSIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 82 RUSSIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 83 RUSSIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 84 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 85 RUSSIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 RUSSIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 87 RUSSIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 88 ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 89 ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 90 ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 91 ITALY HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 92 ITALY BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 93 ITALY IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 94 ITALY LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 95 ITALY HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 96 ITALY HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 97 ITALY HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 98 ITALY HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 99 SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 100 SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 101 SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 102 SPAIN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 103 SPAIN BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 104 SPAIN IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 105 SPAIN LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 106 SPAIN HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 107 SPAIN HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 108 SPAIN HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 109 SPAIN HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 TURKEY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 111 TURKEY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 112 TURKEY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 113 TURKEY HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 114 TURKEY BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 115 TURKEY IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 116 TURKEY LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 117 TURKEY HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 118 TURKEY HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 119 TURKEY HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 120 TURKEY HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 121 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 122 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 123 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 124 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 125 NETHERLANDS BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 126 NETHERLANDS IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 127 NETHERLANDS LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 128 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 129 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 130 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 131 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 132 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 133 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 134 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 135 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 136 SWITZERLAND BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 137 SWITZERLAND IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 138 SWITZERLAND LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 139 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 140 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 141 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 142 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 143 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 144 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 145 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 146 BELGIUM HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 147 BELGIUM BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 148 BELGIUM IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 149 BELGIUM LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 150 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 151 BELGIUM HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 152 BELGIUM HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 153 BELGIUM HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 154 REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 2 EUROPE HEREDITARY CANCER TESTING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HEREDITARY CANCER TESTING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HEREDITARY CANCER TESTING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HEREDITARY CANCER TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HEREDITARY CANCER TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HEREDITARY CANCER TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE HEREDITARY CANCER TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE HEREDITARY CANCER TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 11 EXPANDING REPRODUCTIVE GENETIC HEALTH SPACE IS EXPECTED TO DRIVE THE EUROPE HEREDITARY CANCER TESTING MARKET IN THE FORECAST PERIOD
FIGURE 12 MULTI PANEL TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HEREDITARY CANCER TESTING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE HEREDITARY CANCER TESTING MARKET
FIGURE 14 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2021
FIGURE 15 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, CAGR (2022-2029)
FIGURE 17 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2021
FIGURE 19 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, LIFELINE CURVE
FIGURE 22 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2021
FIGURE 23 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 24 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 25 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2021
FIGURE 27 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 29 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 30 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, 2021
FIGURE 31 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 32 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, CAGR (2022-2029)
FIGURE 33 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 36 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE HEREDITARY CANCER TESTING MARKET: SNAPSHOT (2021)
FIGURE 39 EUROPE HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021)
FIGURE 40 EUROPE HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 EUROPE HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE (2022-2029)
FIGURE 43 EUROPE HEREDITARY CANCER TESTING MARKET: COMPANY SHARE 2021 (%)
